SPY334.19+5.46 1.66%
DIA275.90+4.20 1.55%
IXIC11,117.53+203.96 1.87%

Odonate Therapeutics shares are trading higher after the company announced the results from CONTESSA, a phase 3 study of Tesetaxel, achieved the primary endpoint. UPDATE: Shares have reversed since then.

Benzinga · 08/24/2020 12:02